Navigation Links
Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
Date:2/1/2010

TSX Exchange Symbol: RVX

CALGARY, Feb. 1 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that the Board of Directors has elected Arthur J. Higgins, CEO of Bayer HealthCare and Chairman of the Bayer HealthCare Executive Committee, to the Board effective February 1, 2010.

Mr. Higgins joined Bayer in 2004 as Chairman of the Bayer HealthCare Executive Committee and in 2006 was named Chairman of the Board of Management of Bayer HealthCare. Mr. Higgins has played a key role in driving the success of Bayer HealthCare through a combination of strong organic growth and key acquisitions, including the (euro)17 billion acquisition of the German pharmaceutical company, Schering AG, in 2006.

"Arthur Higgins' global leadership experience and exposure to numerous healthcare markets are just a few of the reasons that he is a valued addition to the Board," said Donald J. McCaffrey, President & CEO of Resverlogix. "As we progress through our Phase 2 clinical trials, we welcome Mr. Higgins' perspective as a strategist and R&D specialist."

Mr. Higgins was born in Airdrie, Scotland. He studied at Scotland's Strathclyde University from 1974 to 1978, where he gained a Bachelor of Science degree in biochemistry.

Mr. Higgins started his career in 1978 in England with Bristol-Myers. He subsequently worked for Sandoz (1979 to 1984) and Fisons (1984 to 1987) before moving to Abbott Laboratories in the USA (1987 to 2001), where he held various positions of increasing responsibility in the international and domestic divisions, including a two-year posting in Germany. He was appointed President of the Pharmaceutical Products Division in Chicago, Illinois, USA, in 1998. In this position, he was in charge of Abbott's pharmaceuticals business in the United States with responsibility for global pharmaceutical research and development.

In 2001, Mr. Higgins was appointed Chairman and CEO of Enzon Pharmaceuticals headquartered in Bridgewater, New Jersey, USA. In this function, he also served as Chairman of the Biotech Council of New Jersey and on the board of the U.S. National Pharmaceutical Council.

Mr. Higgins represents Bayer in the Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA), and is also a member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

From May 2007 until December 2009, Mr. Higgins was President of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE Resverlogix Corp.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Techne Corporation Announces the Retirement of G. Arthur Herbert, a Member of Its Board of Directors
2. Insulet Appoints Bill Arthur as Vice President of Business Development
3. Ikaria Founding Scientist Named 2007 MacArthur Fellow
4. Basic Scientist Mark Roth Wins MacArthur Fellowship
5. Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process
6. Inspiring New Online Destination From Bayer Diabetes Care
7. Bayer Acquires Two Prescription Dermatology Product Lines From SkinMedica in the U.S.
8. Bayer CropScience Announces Investment of $25 Million for Institute Site
9. Bayers CONTOUR and Bayers BREEZE2 Blood Glucose Monitoring Systems Do Not Use Problematic GDH-PQQ Technology
10. DuPont and Bayer CropScience Expand Collaboration With Broad License Agreements
11. Neptune Products to be commercialized by BAYER HealthCare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017 The global biotechnology services outsourcing ... by 2025, according to a new report by ... adaptive of the function of outsourcing certain clinical ... the services outsourced, clinical trial management and contract ... Johnson was the first pharmaceutical company to outsource ...
(Date:1/19/2017)... 2017 BD (Becton, Dickinson and Company) (NYSE: ... will host a live webcast of its Annual Meeting of Shareholders ... The webcast can be accessed from the BD corporate website ... January 31, 2017. ... About BD BD is a global medical technology company ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017   Boston ... novel compounds designed to target cancer stemness pathways, will ... investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers ... Francisco . Napabucasin is an ... by targeting STAT3. i Cancer stem cells (CSCs) ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive ... 2017 in its continued commitment to the advancement of the clinical trials segment. ... issues related to clinical trial planning and management. , As executive talent ...
Breaking Biology Technology:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):